Many liver diseases are associated with endocrine disorders, including nonalcoholic fatty liver disease (NAFLD), autoimmune hepatitis and primary biliary cirrhosis. NAFLD is the most common liver disorder worldwide and its rising prevalence mirrors that of obesity and type 2 diabetes. Thyroid disorders are often associated with hepatic alterations. Chronic liver disease can impair menstruation and fertility. In addition, patients with diabetes have a higher prevalence of significant liver fibrosis and enhanced risk of disease progression to cirrhosis and hepatocellular carcinoma. Management of these disorders should consider the relationship between the liver and the endocrine system, in order to address all manifestations and complications.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Liver Disorders Content
Lise Lotte Gluud, EASD 2021: Effect of Subcutaneous Semaglutide on Features of the Metabolic Syndrome in Patients with Non-alcoholic Steatohepatitis
touchENDOCRINOLOGY caught up with Prof Lise Lotte Gluud (Copenhagen University Hospital, Hvidovre, Denmark) virtually during the EASD Annual Meeting 2021 conference to discuss her study on the effect of subcutaneous semaglutide on features of the metabolic syndrome in patients with non-alcoholic steatohepatitis. Questions 1. Could you give us a brief overview of the association of […]
Quentin Anstee: Highlights from the Digital NAFLD Summit 2021
touchENDOCRINOLOGY joins Professor Quentin Anstee (Newcastle University, UK) at the Digital NAFLD Summit 2021 to discuss his highlights from the conference and new, exciting developments in the field. Questions 1. Are you pleased with how the European Association for the Study of the Liver (EASL) NAFLD Summit 2021 went this year? (00:23-01:00) 2. What were […]
Quentin Anstee, Digital NAFLD Summit 2021: Exciting Advances and New Research into the Management of Non-alcoholic Fatty Liver Disease
touchENDOCRINOLOGY joins Prof. Quentin Anstee (Newcastle University, UK) at the Digital NAFLD Summit 2021 to discuss his highlights from the conference and new, exciting developments in the field. Questions 1. Please summarise the prevalence of non-alcoholic fatty liver disease (NAFLD) and the clinical unmet needs in this area? (0:20) 2. What are the current most […]
Jean-François Dufour, UEG 2021: Treatment Pipeline for NASH
It was a pleasure to speak with Prof. Jean-François Dufour (University of Bern, Bern, Switzerland) about drug development in non-alcoholic steatohepatitis (NASH) and in particular the farnesoid X receptor (FXR) as a therapeutic target. His presentation entitled ‘Treatment of NASH: What is in the pipeline?’ was given at UEG week, 2-5 Oct 2021. Questions What […]
Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice
touchREVIEWS in Endocrinology. 2021;1(2):112–20 DOI: https://doi.org/10.17925/EE.2021.17.2.112
Non-alcoholic fatty liver disease (NAFLD) consists of non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). It is unclear which specific patients progress from NAFL to NASH and, ultimately, to cirrhosis. However, there is general consensus that, for those patients who do progress to cirrhosis (fibrosis stage 4), there is an increased risk of liver-related complications […]
Luca Valenti, NAFLD Summit 2021: The Latest Advances in NAFLD
TouchENDOCRINOLOGY joins Prof Luca Valenti (University of Milan, Italy) at the Digital NAFLD Summit 2021 to discuss his hopes for the conference and the most exciting new developments in the field of non-alcoholic fatty liver disease (NAFLD). Questions Could you give us an overview of the clinical spectrum of non-alcoholic fatty liver disease (NAFLD) and […]
Rohit Loomba, EASL ILC 2021: Pemafibrate Phase 2 Results in NAFLD
We continue our discussion with Prof. Rohit Loomba (University of California, San Diego, CA, USA) by exploring the results for the phase 2 study investigating pemafibrate in NAFLD. Part 1 of our video interview can be found here. His presentation entitled ‘Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM alpha), improves liver stiffness […]
Rohit Loomba, EASL ILC 2021: Rationale for Pemafibrate in NAFLD
It was a pleasure to speak with Prof. Rohit Loomba (University of California, San Diego, CA, USA) about the rationale for the use of the novel SPPARM inhibitor, pemafibrate, in the treatment of NAFLD. Part 2 of our discussion can be found here. His presentation entitled ‘Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator […]
Sven Francque, EASL ILC 2021: Lanifibranor NATIVE Subgroup Analysis
Prof. Dr Sven Francque (University of Antwerp, Belgium) kindly spoke with us about the additional analysis of the phase 2b NATIVE trial investigating lanifibranor in patients with NASH. His presentation entitled ‘Lanifibranor therapy improves markers of lipid metabolism, insulin resistance, liver injury and fibrosis in patients with NASH and F2 and F3 fibrosis stages: a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!